Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
135.3 EUR | +0.88% | -0.01% | -4.38% |
08:52pm | US lawmakers ask FBI for briefing on GenScript Biotech's links to China | RE |
08:05pm | Sector Update: Health Care Stocks Advance Friday Afternoon | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an enterprise value anticipated at 3.89 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.38% | 350B | - | ||
+39.61% | 734B | C+ | ||
+32.83% | 591B | B | ||
+14.78% | 315B | B- | ||
+2.28% | 276B | C+ | ||
+15.00% | 238B | B+ | ||
+9.78% | 206B | B- | ||
-5.52% | 204B | A+ | ||
+5.24% | 161B | C+ | ||
-1.20% | 160B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson